In a current examine posted to the medRxiv pre-print* server, a workforce of researchers evaluated the effectiveness of the XBB.1.5 coronavirus illness 2019 (COVID-19) vaccine in decreasing hospitalizations and Intensive Care Unit (ICU) admissions amongst beforehand vaccinated adults aged 60 and over within the Netherlands from October to December 2023.
Examine: Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine towards hospitalization and ICU admission, the Netherlands, 9 October – 5 December 2023. Picture Credit score: NIAID
*Essential discover: medRxiv publishes preliminary scientific stories that aren’t peer-reviewed and, subsequently, shouldn’t be considered conclusive, information medical follow/health-related habits, or handled as established data.
Background
In 2023, the Netherlands initiated its seasonal COVID-19 vaccination marketing campaign on October 2, specializing in people 60 years and older, healthcare employees, pregnant ladies, and people with medical dangers utilizing the XBB1.5 Comirnaty vaccine. Private vaccination invites had been mailed to residents 60+ from early October to late November. As of early December, 42.9% of this demographic had been vaccinated, and the marketing campaign is about to proceed till the tip of December. Additional analysis is important to completely perceive the long-term effectiveness and impression of the XBB.1.5 COVID-19 vaccine on hospitalization and ICU admission charges, particularly as the continuing seasonal vaccination marketing campaign progresses and extra information turns into obtainable post-December 2023.
Concerning the examine
The analysis workforce employed the screening technique to evaluate the vaccine effectiveness (VE) of the 2023 seasonal COVID-19 vaccination amongst people aged 60 and older within the Netherlands who had obtained not less than one prior COVID-19 vaccination. The evaluation targeted on these recorded within the nationwide inhabitants register as of September 25, 2023. Hospitalization information, overlaying the interval from October 9 to December 5, 2023, had been sourced from the Nationwide Institute for Well being and Care Excellence (NICE) COVID-19 database on December 11, 2023, to permit for reporting delays. This dataset accounted for about 55% of all COVID-19 hospitalizations within the Netherlands in the course of the examine interval, in line with comparisons with nameless information from the Nationwide Coordination Heart for Affected person Distribution.
Hospitalization data had been deterministically linked to the nationwide COVID-19 vaccination database (CIMS) through the Citizen Service Quantity. The CIMS registry, which depends on vaccine consent for recording vaccinations, confirmed a consent charge of over 95% in earlier booster campaigns and 98% for the 2023 seasonal marketing campaign. Alternatively, people included on this examine who had not less than one vaccination recorded in CIMS since January 2021 anticipated that these folks would additionally consent to document their present 12 months’s (seasonal) vaccine doses and, subsequently, scale back classification errors.
Though the official begin of the 2023 seasonal vaccination marketing campaign within the Netherlands was October 2, some facilities started vaccinations as early as September 25, which had been included within the marketing campaign evaluation. People vaccinated inside 90 days earlier than September 25 had been excluded. To account for the vaccine’s immunological response time, an individual’s standing was up to date to “seasonal dose obtained” seven days post-vaccination, excluding this era from the evaluation. The vaccination standing was equally decided at hospital admission. Utilizing the CIMS registry, the vaccinated inhabitants’s proportion was calculated, stratified by area, date, intercourse, and age up till the fifteenth of the month of demise, emigration, or examine finish.
A logistic regression mannequin estimated VE and its 95% confidence intervals. On this mannequin, vaccination standing was the dependent variable, and the covariate-specific logit of the seasonal dose obtained within the inhabitants served as an offset. The mannequin’s exponentiated intercept was interpreted because the relative threat (RR), and VE was calculated as (1-RR) x 100%.
VE estimates
The 2023 seasonal COVID-19 vaccination marketing campaign within the Netherlands focused on high-risk teams, akin to these aged 60 and above. Of those, the examine excludes 86 hospitalizations (together with three ICU admissions) inside seven days post-vaccination, and included of their evaluation are a complete of two,050 instances admitted to hospitals. Amongst them, 295 (14.4 %) had obtained the seasonal COVID-19 vaccine for 2023. It was discovered that there have been extra hospitalizations amongst these aged 75 and older than within the age group of 60-74. Throughout the course of the marketing campaign, hospitalizations amongst vaccinated individuals have elevated progressively; this clearly displays {that a} large-scale rollout is underway.
The VE towards hospitalization was 70.7 % (CI, 66.6 to 74.3). Among the many 92 instances of ICU admissions analyzed, VE was estimated at roughly 73.3 % (CI 42.2 to 87.6). The VE for the 60-74 age group (VE = 68.3%, CI :58.3 to 75.9) was barely decrease than that of these aged seventy-five and over (VE=V:Y%). In contrast with final 12 months’s fall marketing campaign, this examine’s VE estimates had been barely greater for these aged 60-79.
The researchers utilized the screening technique, contemplating the unfinished information from the NICE hospitalization database as a result of registration burden on hospitals. They included geographic areas within the mannequin to regulate for doable variations in information completeness. Nevertheless, there have been limitations which may have led to an underestimation of VE, akin to the shortcoming to regulate for comorbidities, which usually ends in greater VE estimates. Moreover, the examine’s preliminary interval probably represented early vaccine recipients, who may need been frailer. The vaccination standing of instances was decided on the time of hospitalization, which could not have allowed ample time for the vaccine to forestall extreme illness.
In distinction, there may need been an overestimation of VE as a result of usually higher well being of vaccine recipients (wholesome vaccine bias). The examine additionally famous that the majority people obtained their fourth booster dose in the course of the marketing campaign, with solely 0.2% receiving a fifth booster. The median time because the final booster dose was considerably totally different between those that had and had not obtained the 2023 vaccine, doubtlessly affecting VE estimates. Nevertheless, a examine throughout six European nations indicated that the variety of booster doses didn’t considerably impression VE towards hospitalization, and effectiveness usually waned six months after any booster dose.
*Essential discover: medRxiv publishes preliminary scientific stories that aren’t peer-reviewed and, subsequently, shouldn’t be considered conclusive, information medical follow/health-related habits, or handled as established data.
